Alexander Hacopian, MD
Ophthalmology · Washington, DCNPI 1487009866
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,921 of the $12,821 with a category attached, or 69.6%. It is spread thinly across 25 manufacturers, the largest accounting for just 23.8%. Among ophthalmology clinicians in DC with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 261 payments — averaging $49.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Glaukos Corporation$3K
- Alcon$3K
- AbbVie$3K
- Johnson & Johnson Surgical Vision, Inc.$690
- Tarsus Pharmaceuticals, Inc.$612
- Sun Pharmaceutical Industries Inc.$518
- plus $3K from 19 others
Across 2 payments — averaging $58,170 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Alcon Research LLC$116K
What the payments were for
- Consulting fees$9007%
- Grants$3,00023%
- Food & beverage$8,92170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Glaukos Corporation | 3 | $3,050 |
| Alcon | 79 | $2,792 |
| AbbVie(2 entities) | 69 | $2,558 |
| Johnson & Johnson Surgical Vision, Inc. | 13 | $690 |
| Tarsus Pharmaceuticals, Inc. | 8 | $612 |
| Sun Pharmaceutical Industries Inc. | 12 | $518 |
| NEW World Medical,inc. | 11 | $406 |
| Oyster Point Pharma, Inc. | 7 | $239 |
| Carl Zeiss Meditec Cataract Technology Inc. | 2 | $214 |
| Bausch & Lomb Americas Inc. | 9 | $211 |
| Carl Zeiss Meditec USA, Inc. | 2 | $177 |
| Biotissue Holdings Inc. | 7 | $172 |
| Aerie Pharmaceuticals, Inc. | 6 | $165 |
| Dompe US, Inc. | 2 | $150 |
| Amgen | 1 | $150 |
| Sight Sciences, Inc. | 7 | $138 |
| Rayner Intraocular Lenses Limited | 5 | $134 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 6 | $106 |
| Optos, Inc. | 1 | $93 |
| Thea Pharma Inc. | 3 | $67 |
| Novartis | 3 | $61 |
| Harrow Eye, LLC | 2 | $51 |
| Kala Pharmaceuticals, Inc. | 1 | $24 |
| Astellas Pharma US Inc | 1 | $23 |
| Eyepoint US, Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DURYSTA$900
- CEQUA$363
- Hydrus Microstent$358
- TEPEZZA$150
- Tecnis Simplicity$148
- Unity$144
- TYRVAYA$125
- Oxervate$125
- LUMIGAN$125
- VUITY$125
- Clareon$112
- Tecnis IOL$104
- Wavelight Refractive Suite$101
How this compares
$12,821 in reported general payments places this provider in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 38 | $36,289 |
| LumiganBimatoprost | 57 | $28,540 |
| XdemvyLotilaner | 13 | $24,240 |
| XiidraLifitegrast | 24 | $22,111 |
| RocklatanNetarsudil Mesylat/Latanoprost | 16 | $7,353 |
| Brimonidine Tartrate | 55 | $4,817 |
| Loteprednol Etabonate | 28 | $4,790 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 18 | $2,893 |
| Prednisolone Acetate | 61 | $2,871 |
| Lotemax SmLoteprednol Etabonate | 11 | $2,742 |
| Latanoprost | 106 | $1,420 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 47 | $701 |
| Timolol Maleate | 49 | $505 |
| MoxifloxacinMoxifloxacin Hcl | 15 | $299 |
| Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha | 14 | $119 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $2,558 | $64,83095 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $612 | $24,24013 claims |
| Bausch & Lomb Americas Inc.Xiidra | $211 | $22,11124 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate, Lotemax Sm | $106 | $7,53239 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan | $165 | $7,35316 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 74 ophthalmology providers in District of Columbia.
Other ophthalmology in Washington
- Wiley ChambersWashington$618K
- Keesha Williams ElliottWashington$167K
- Samuel StopakWashington$33K
- Jonca BullWashington$30K
- Leslie JonesWashington$22K
- Mehdi Tavakoli DastjerdiWashington$12K
- Andrew HammerWashington$11K
- Thandeka MyeniWashington$10K
- Dipak PanigrahiWashington$9K
- Jared EbertWashington$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.